Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

More on GLP-1 receptor agonists

More on GLP-1 receptor agonists

05-26-2022 | Insulin glargine | News

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

05-19-2022 | Semaglutide | News

Semaglutide offers alternative to prandial insulin in type 2 diabetes

05-09-2022 | Semaglutide | News

Bodyweight rebounds after semaglutide withdrawal

05-07-2022 | Semaglutide | Adis Journal Club | Article

Oral Semaglutide: Dosage in Special Situations

05-03-2022 | GLP-1 agonists | Adis Journal Club | Article

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

04-08-2022 | DUKPC 2022 | Conference coverage | News

Within-class switch to semaglutide brings benefits in real-world cohort

04-01-2022 | Semaglutide | News

Higher semaglutide dose approved in USA

03-08-2022 | Semaglutide | Adis Journal Club | Article

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)

02-25-2022 | GLP-1 agonists | News

Real-world weight loss with GLP-1 receptor agonists lags behind clinical trials

02-07-2022 | Semaglutide | News

STEP 6: Semaglutide addresses ‘pathophysiology of metabolic syndrome’ in east Asians

02-04-2022 | Cardiovascular outcomes | News

Real-world data support SGLT2 inhibitors, GLP-1 receptor agonists for primary CVD prevention

01-11-2022 | Semaglutide | News

STEP 8: Semaglutide better than liraglutide at weight-management doses

12-16-2021 | GLP-1 agonists | Adis Journal Club | Article

Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)

12-06-2021 | Exenatide | News

Cardiovascular safety shown for continuous subcutaneous exenatide infusion

11-26-2021 | Efpeglenatide | News

Efpeglenatide CV benefits independent of SGLT-2 inhibitor use

11-17-2021 | Semaglutide | News

Semaglutide 2.4 mg receives EMA approval for obesity

10-22-2021 | Healthcare costs | News

SGLT2 inhibitor cost-effectiveness feasible in low-, middle-income countries

10-13-2021 | Liraglutide (T2DM) | News

Liraglutide add-on may offer better control than OADs in type 2 diabetes

10-07-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

10-05-2021 | EASD 2021 | Conference coverage | News

Semaglutide treatment may reduce systemic inflammation
Next Previous